NEWS & INSIGHTS

UntilAllSurvive.com: where cancer survivors share their inspiring stories

The patients

Publication Date:
TO READ NEXT

How Patient Diversity in Clinical Trials Improves Cancer Research

UntilAllSurvive.com: Discover exceptional survivors' stories, explore the science inspired by their experiences and meet the patients, researchers and clinicians working toward a future where more people survive cancer.

🔗 UntilAllSurvive.com


Updated: August 4, 2026

Table of Contents
in THIS ARTICLE
In this article

Yann Bizien

Patient Committee Manager

MORE ARTICLES IN THIS TOPIC
RELATED ARTICLES
yann-bizien-chloe-abadachi-cancer

Yann Bizien: 9 Years After a Stage IV Pancreatic Cancer Diagnosis

yann-bizien-chloe-abadachi-cancer

Yann Bizien: 9 Years After a Stage IV Pancreatic Cancer Diagnosis

until-all-survive-website-for-cancer-patients

UntilAllSurvive.com: we're launching a new website for cancer patients!

until-all-survive-website-for-cancer-patients

UntilAllSurvive.com: we're launching a new website for cancer patients!

yann_bizien_science_illustrated

Our Patient Committee is a key part of our scientific approach

yann_bizien_science_illustrated

Our Patient Committee is a key part of our scientific approach

NEWS & INSIGHTS

Cure51 and Servier sign a long-term Target ID partnership on Glioblastoma in a deal up to €442M per target to discover novel therapies.

marine-otero-del-val-chloe-monvoisin-nicolas-bonneau-cure51-product

Building a Product Ecosystem for Cancer Target Discovery

CHUV-Centre-hospitalier-universitaire-vaudois

CHUV Lausanne received their Rosalind trophy!

Explore more

Ashley-Lakner-cure51-servier

ASHLEY LAKNER, CSO: “OUR PARTNERSHIP WITH SERVIER OPENS NEW OPPORTUNITIES TO IDENTIFY THERAPEUTIC TARGETS FOR GLIOBLASTOMA”

READ MORE

Cure51 and Servier sign a long-term Target ID partnership on Glioblastoma in a deal up to €442M per target to discover novel therapies.

marine-otero-del-val-chloe-monvoisin-nicolas-bonneau-cure51-product

Building a Product Ecosystem for Cancer Target Discovery

CHUV-Centre-hospitalier-universitaire-vaudois

CHUV Lausanne received their Rosalind trophy!

Explore more

Ashley-Lakner-cure51-servier

ASHLEY LAKNER, CSO: “OUR PARTNERSHIP WITH SERVIER OPENS NEW OPPORTUNITIES TO IDENTIFY THERAPEUTIC TARGETS FOR GLIOBLASTOMA”

READ MORE

OUR TOP STORIES

NEWS & INSIGHTS

NEWS & INSIGHTS

Cure51 and Servier sign a long-term Target ID partnership on Glioblastoma in a deal up to €442M per target to discover novel therapies.

marine-otero-del-val-chloe-monvoisin-nicolas-bonneau-cure51-product

Building a Product Ecosystem for Cancer Target Discovery

CHUV-Centre-hospitalier-universitaire-vaudois

CHUV Lausanne received their Rosalind trophy!

Explore more

Ashley-Lakner-cure51-servier

ASHLEY LAKNER, CSO: “OUR PARTNERSHIP WITH SERVIER OPENS NEW OPPORTUNITIES TO IDENTIFY THERAPEUTIC TARGETS FOR GLIOBLASTOMA”

READ MORE

UNTIL ALL SURVIVE.

From frontline caregivers and patients to researchers and media voices, we bring diverse perspectives together to advance cancer research. Let’s talk.

Contact us

UNTIL ALL SURVIVE.

Rosalind is an independent, proprietary Cure51 clinical study and is not affiliated with any external AI models or products.

©2024 Cure51, All Rights Reserved

©2026 Cure51, All Rights Reserved

Rosalind is an independent, proprietary Cure51 clinical study and is not affiliated with any external AI models or products.

Contact us

Contact us

ROSALIND

Contact us